{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:56:40Z","timestamp":1790539000743,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jns.2026.126183","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:19:13Z","timestamp":1790003953000},"page":"126183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Meningococcal infection in patients receiving eculizumab or ravulizumab for generalized myasthenia gravis or neuromyelitis optica spectrum disorder: A real-world study of US clinical practice"],"prefix":"10.1016","volume":"491","author":[{"given":"Shirali","family":"Pandya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lokesh","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ukwen","family":"Akpoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghana","family":"Koneru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samirah","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Carrillo Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jns.2026.126183_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9040399","article-title":"Emerging role of C5 complement pathway in peripheral neuropathies: current treatments and future perspectives","volume":"9","author":"Giorgio","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jns.2026.126183_bb0010","series-title":"Soliris (Eculizumab) [Prescribing Information]","year":"2025"},{"key":"10.1016\/j.jns.2026.126183_bb0015","series-title":"Ultomiris (Ravulizumab) [Prescribing Information]","year":"2025"},{"issue":"6","key":"10.1016\/j.jns.2026.126183_bb0020","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"133","author":"Lee","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jns.2026.126183_bb0025","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.jns.2026.126183_bb0030","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/acn3.51376","article-title":"Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses","volume":"8","author":"Howard","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2026.126183_bb0035","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70158","article-title":"Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: final results from the phase 3 CHAMPION MG open-label extension","volume":"32","author":"Vu","year":"2025","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2026.126183_bb0040","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/13524585211038291","article-title":"Eculizumab monotherapy for NMOSD: data from PREVENT and its open-label extension","volume":"28","author":"Pittock","year":"2022","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.jns.2026.126183_bb0045","article-title":"Ravulizumab is effective and safe for neuromyelitis optica spectrum disorder patients in various clinical settings: a single-center case series with concomitant use of rituximab","volume":"17","author":"Amano","year":"2025","journal-title":"Cureus"},{"issue":"9","key":"10.1016\/j.jns.2026.126183_bb0050","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.1007\/s00415-024-12569-w","article-title":"United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use","volume":"271","author":"Habib","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2026.126183_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2025.123628","article-title":"First analysis of the myasthenia gravis SPOTLIGHT registry: outcomes with eculizumab and ravulizumab","volume":"476","author":"Howard","year":"2025","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2026.126183_bb0060","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231181177","article-title":"Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan","volume":"16","author":"Nakashima","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"9","key":"10.1016\/j.jns.2026.126183_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6909a1","article-title":"Meningococcal vaccination: recommendations of the advisory committee on immunization practices, United States, 2020","volume":"69","author":"Mbaeyi","year":"2020","journal-title":"MMWR Recomm. Rep."},{"key":"10.1016\/j.jns.2026.126183_bb0070","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.jns.2026.126183_bb0075","author":"Schillie"},{"issue":"15","key":"10.1016\/j.jns.2026.126183_bb0080","doi-asserted-by":"crossref","first-page":"345","DOI":"10.15585\/mmwr.mm7315a4","article-title":"Use of the Pfizer pentavalent meningococcal vaccine among persons aged \u226510 years: recommendations of the advisory committee on immunization practices - United States, 2023","volume":"73","author":"Collins","year":"2024","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"issue":"49","key":"10.1016\/j.jns.2026.126183_bb0085","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.15585\/mmwr.mm7349a3","article-title":"New dosing interval and schedule for the Bexsero MenB-4C vaccine: updated recommendations of the advisory committee on immunization practices - United States, October 2024","volume":"73","author":"Schillie","year":"2024","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"10.1016\/j.jns.2026.126183_bb0090","series-title":"MenABCWY for the prevention of invasive meningococcal disease caused by serogroups a, B, C, W and Y [presentation]","author":"Sohn","year":"2024"},{"issue":"11","key":"10.1016\/j.jns.2026.126183_bb0095","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae638","article-title":"4CMenB breadth of immune response, immunogenicity, and safety: results from a phase 3 randomized, controlled, observer blind study in adolescents and young adults","volume":"11","author":"Nolan","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.jns.2026.126183_bb0100","series-title":"Penmenvy [Package Insert]","year":"2025"},{"key":"10.1016\/j.jns.2026.126183_bb0105","author":"Schillie"},{"issue":"9","key":"10.1016\/j.jns.2026.126183_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0332073","article-title":"Eculizumab and ravulizumab clinical trial and real-world pharmacovigilance of meningococcal infections across indications","volume":"20","author":"Carrillo Infante","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2026.126183_bb0125","series-title":"Soliris (Eculizumab) [Summary of Product Characteristics]","year":"2025"},{"key":"10.1016\/j.jns.2026.126183_bb0130","series-title":"Ultomiris (Ravulizumab) [Summary of Product Characteristics]","year":"2025"},{"issue":"4","key":"10.1016\/j.jns.2026.126183_bb0135","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200644","article-title":"Comprehensive care goals in myasthenia gravis: expert consensus recommendations using the RAND\/UCLA appropriateness method","volume":"16","author":"Narayanaswami","year":"2026","journal-title":"Neurol. Clin. Pract."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2600465X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2600465X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:22:01Z","timestamp":1790536921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X2600465X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":25,"alternative-id":["S0022510X2600465X"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.126183","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meningococcal infection in patients receiving eculizumab or ravulizumab for generalized myasthenia gravis or neuromyelitis optica spectrum disorder: A real-world study of US clinical practice","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.126183","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Alexion, AstraZeneca Rare Disease. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"126183"}}